Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

Background: Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly high-grade prostate cancer. One study reported that men with low cholesterol had a lower risk of high-grade prostate cancer. Given these findings, we...

Full description

Saved in:
Bibliographic Details
Published in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2009-11, Vol.18 (11), p.2807-2813
Main Authors: PLATZ, Elizabeth A, TILL, Cathee, GOODMAN, Phyllis J, PARNES, Howard L, FIGG, William D, ALBANES, Demetrius, NEUHOUSER, Marian L, KLEIN, Eric A, THOMPSON, Ian M, KRISTAL, Alan R
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Case-Control Studies
cholesterol
Cholesterol - blood
Cohort Studies
Disorders of blood lipids. Hyperlipoproteinemia
Humans
Male
Medical sciences
Metabolic diseases
Middle Aged
Placebos
Prognosis
Prospective Studies
prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
Prostatic Neoplasms - prevention & control
risk
Risk Factors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly high-grade prostate cancer. One study reported that men with low cholesterol had a lower risk of high-grade prostate cancer. Given these findings, we investigated the association between low serum cholesterol and prostate cancer risk in the Prostate Cancer Prevention Trial. Methods: We conducted a cohort study of 5,586 men ages ≥55 years who were randomized to the placebo arm of the Prostate Cancer Prevention Trial between 1993 and 1996. Serum cholesterol was measured enzymatically at entry. By the end of follow-up, 1,251 prostate cancer cases were confirmed. We used logistic regression to calculate the multivariable odds ratio (OR) of total, and Gleason 2 to 6 ( n = 993), 7 ( n = 199), and 8 to 10 ( n = 59) prostate cancer comparing low serum (normal,
ISSN:1055-9965
1538-7755
DOI:10.1158/1055-9965.EPI-09-0472